Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vanderbilt University Medical Center
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT) is a randomized study to investigate blood sparing using autologous normovolemic hemodilution (ANH) or cell salvage at the time of nephrectomy for locally advanced kidney cancer after assessing inclusion criteria patients will be randomized to undergo standard blood management including the possibility of allogenic transfusion vs autologous blood transfusion. There are multiple ways patients can receive allogenic or autologous blood, including veno-venous bypass or cardiopulmonary bypass (typically reserved for patients with a thrombus above the level of the hepatic veins or entering the heart).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Renal masses ≥ cT2 (by any conventional imaging).
N1 or M1 disease is allowed if they are deemed surgical candidates (including cytoreductive nephrectomy).
Male and female patients.
18 and older.
Ejection fraction (EF) ≥ 45% by echocardiogram (ECHO).